Date: June 24, 2019

Dr. Nidal Alasaad
Chairman of Cardiology Medical Heart Hospital
Hamad Medical Corporation

This letter is in reference to the clinical trial entitled "Effect of Combination Therapy with Dapagliflozin plus Low Dose Pioglitazone on Hospitalization Rate in Patients with Type 2 Diabetes Mellitus and Preserved Left Ventricular Ejection Fraction Heart Failure " Submitted by HMC on 11 April 2019 and file completed on 26 May 2019.

Research proposal	Document initially reviewed
Protocol number IRGC-04-SI-17-116	Abhath Application IRGC-04-SI-17-116_ResearchProtocol_V1 IRGC-04-SI-17-116_ResearchProtocol_MODIFIED IRB Approval Letter IRGC-04-SI-17-116_DataCollectionSheet_Eng_07-APR-19_21Pages_918669 (1) IRGC-04-SI-17-116_DataCollectionSheet_Eng_24-FEB-19_1Pages_501760 (2) IRGC-04-SI-17-116_DSMBPlan_Eng_V1 IRGC-04-SI-17-116_ResearchConsentForm_Ara IRGC-04-SI-17-116_ResearchConsentForm_Eng Members_DSMB_116 Memo_PatientSafetyForStudy116_toMoPH SupportingDocument_LiteratureList

Upon review of the submitted documents, the Ministry of Public Health (MoPH) support the conduct of this clinical trial under the condition of the strict adherence to the bellow condition. Please be noted that it is the institution, sponsor and the principal investigator's responsibility, to ensure that this clinical trial is conducted in compliance with MoPH regulations and the principle of International Conference on Harmonization(ICH)- Good Clinical Practice(GCP), and to ensure the below responsibilities are fulfilled:

The PI's responsibilities

1- The safety and well being of the participants are protected
2- Research involving human participants begins only after IRB review and approval
3- The research is conducted in accordance with the local IRB-approved protocol, including the approved recruitment and consent procedures
4- When informed consent is required, it is obtained and documented before research participation begins
5- All unanticipated problems, including adverse event(s) are reported in accordance with IRB's policy on reporting unanticipated problems including adverse events

6- All investigators and study staff listed on the project are informed of changes and unanticipated problems, including adverse events, involving risks to subjects or others
7- The continuing review submission to the IRB should be submitted with a sufficient time to allow for IRB review and approval and provide an opportunity for response by the principal investigator to any stipulation of the local registered IRB
8- When the research protocol ends, a final report is submitted to the IRB
9- Adequate and accurate research records are kept and retained
10- The confidentiality of data is maintained at all times
11- Upon request for audit, monitoring and oversight of the research, research records are made available to MoPH
12- When supervising the conduct of the research , The PI ensures that study personnel :
    - Are qualified by training and experience , and credential if necessary to perform study-related tasks that have been assigned to them,
    - Are aware of regulatory and policy requirement and standards for conduct of human subjects research
    - Have a complete understanding of the details of the protocol relevant to the tasks they will be performing
    - Follow the IRB-approved protocol
    - Are informed of any pertinent changes to the protocol during the conduct of the study ans are educated or given additional training, as appropriate.

It is HMC responsibility to:

1. Monitor the safety and wellbeing of research participants
2. Ensure that informed consents are in place
3. Provide enough support to the PI to fulfill his above mentioned responsibilities
4. Protect the privacy and confidentiality of participant
5. Provide the appropriate training to the involved research staff
6. Amendment to the protocol are well documented.
7. Substantial protocol's amendment must be reported to the MoPH. A substantial amendment is defined as an amendment to the terms of the protocol or any other supporting documentation that is likely to affect to a significant degree: (a) the safety of the subjects of the trial, (b) the scientific value of the trial, (c) the conduct or management of the trial.
8. Conduct continuous monitoring during the conduct of the trial
9. Conduct periodic reviews through the trial duration
10. Report all serious adverse events to the MoPH
11. Keep IRB meeting minutes and trial related documents.
12. The MoPH requires that any serious adverse events involving the device under investigation, from all investigational center are reported to the MoPH.
13. The serious adverse event should be notified in accordance with the MOPH regulation: *"Guidelines on Reviewing and Reporting Unanticipated Problems Involving Risks to Subject or Others and Adverse Events"*

It is the Independent Data and Safety Monitoring Board responsibility to:

1- Review the trial prior to its implementation

2- Periodically and regularly review and evaluate the accumulated study data for participant safety, study conduct and progress, and when appropriate, efficacy
3- Make recommendations concerning the continuation, modification, or termination of the trial
4- Ensure that the timeliness, completeness and accuracy of the data submitted to them to review are sufficient for evaluation of the safety and welfare of study participants
5- Share Report resulting from this meeting with HMC-IRB, the sponsor and MOPH

Please note that the MoPH should be notified at the end of the trial, or otherwise if the trial is suspended.

For any enquiries, please contact the Research Division at MoPH via: irb@moph.gov.qa

Sincerely yours,

Neyla Dahane on behalf of

Dr. Eman Sadoun

Manager, Health Research Governance Department

Ministry of Public Health

974-4407-036

dresadoun@MOPH.GOV.QA